Delving into the Latest Updates on Beractant with Synapse

Overview

Basic Info

Drug Type

Biological products

Synonyms

Beractant (USAN), Surfacten

+ [2]

Target-

Mechanism-

Therapeutic Areas

Respiratory DiseasesOther Diseases

Active Indication

Respiratory Distress Syndrome in Premature InfantsRespiratory Distress Syndrome

Inactive Indication-

Originator Organization

AbbVie, Inc.

Active Organization

AbbVie, Inc.Mitsubishi Tanabe Pharma Factory Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

JP (02 Oct 1987),

Respiratory Distress Syndrome

RegulationOrphan Drug (US)

Login to view timeline

A thorough investigation into the biophysical properties of four animal-derived clinical surfactant preparations was conducted through constrained drop surfactometry under physiologically relevant conditions. This comparative study unveiled unique in vitro biophysical characteristics among these clinical surfactants, establishing correlations between their chemical composition, lateral film structure, and biophysical functionality. The acquired knowledge offers essential insights for the precise and personalized design of clinical surfactant for the treatment of respiratory distress syndrome and other respiratory conditions.

01 Apr 2024·American Journal of PerinatologyQ4 · MEDICINE

Pulmonary Complications in Premature Infants Using a Beractant or Poractant for Respiratory Distress Syndrome: A Retrospective Cohort Study

Q4 · MEDICINE

Article

Author: Siu, Kiu Lok ; Wong, Kin Lok

Objective Premature infants are at the risk of developing respiratory distress syndrome (RDS). Beractants and poractants are two commonly used natural surfactants. This retrospective cohort study aims to compare the incidence of pulmonary complications between beractant and poractant treatment groups. Study Design This study evaluated 29 patients treated with beractant and 49 patients treated with poractant. The primary outcome was the incidence of air leak syndrome (ALS) and pulmonary hemorrhage. Secondary outcomes included mortality and pulmonary outcomes, such as mechanical ventilation duration, oxygen dependence duration, fraction of inspired oxygen, and mean airway pressure (MAP) requirement. Logistic regression analyses were conducted to identify independent risk factors for significant primary outcomes. Results No significant difference was found in the demographics between the two groups. A significantly higher incidence of pulmonary hemorrhage was observed in the poractant group (14.3 vs. 0.0%, p = 0.038). The difference in the incidence of ALS between the groups was insignificant (p = 0.536). Logistic regression for the incidence of pulmonary hemorrhage identified coagulopathy as the only significant independent risk factor (odds ratio 39.855, 95% confidence interval [2.912–545.537]; p = 0.006). Secondary outcomes in both treatment groups were similar, except that patients in the poractant group had a higher MAP before surfactant therapy (9 vs. 8 cmH2O, p < 0.001). Conclusion This study showed a significantly higher incidence of pulmonary hemorrhage in the poractant group. Coagulopathy was identified as an independent risk factor for pulmonary hemorrhage. Future long-term prospective studies are essential to establish the temporal and causal relationships between coagulopathy and pulmonary hemorrhage in premature infants receiving surfactant therapy for RDS; hence, there is the need for a screening protocol before surfactant administration. Key Points

28 Feb 2024·Cureus

Predictors of Extubation Failure in Very Low Birth Weight Infants at a Tertiary Care Hospital in Al Ain: A Retrospective Study

Article

Author: Kasem, Sameh ; Siwji, Zohra ; Abu Sa'da, Omar ; Omar, Nuralhuda ; Pappachan, Binu ; Rahmani, Aiman ; Afzal, Uzma ; Varghese, Nisha

OBJECTIVESTo identify and analyze the factors leading to extubation failure among very low birth weight infants in a specific tertiary care setting in Al Ain, emphasizing clinical and demographic variables. The study used medical data of Very Low Birth Weight (VLBW) infants admitted to the Neonatal Intensive Care Unit (NICU) from 1st January 2015 to 31st December 2019, and evaluated the incidence and risk factors associated with extubation failure.METHODSData was collected from the hospital's electronic records and tabulated in Excel sheets, with extubation failure defined as reintubation due to deterioration of respiratory condition within seven days post-extubation. The data was collected from the period of 1st January 2015 to 31st December 2019. Inclusion criteria included babies admitted to the NICU with a gestational age of ≤ 32 weeks, or of birth weight ≤1500 grams who were intubated within the first seven days of life. Results were analyzed using SPSS software, version 9.0 (SPSS Inc., Chicago) to determine the risk factors for extubation failure and short-term outcomes.RESULTSGestational age, birth weight, antenatal steroids, mode of delivery, number of Survanta® (beractant intratracheal suspension) doses, Positive End-Expiratory Pressure (PEEP), Mean Airway Pressure (MAP), Mean Arterial Pressure (Blood Pressure (BP)), and Infectious Diseases (ID) (indicated by a positive blood culture) were found to be the key predictors of extubation failure in very low birth weight infants at a tertiary care hospital in Al Ain. The most common reasons for reintubation were FiO2 > 50% (23.53%), followed by Respiratory Acidosis (20.59%). Other factors, including maternal chorioamnionitis, Apgar scores, indication for intubation, caffeine, and pre-and post-extubation laboratory values, comorbidities, and hemoglobin (Hgb), creatinine and sodium levels were found to have no effect on the success of extubations.CONCLUSIONSThe results of this research indicate that factors such as gestational age, birth weight, prenatal steroid use, delivery method, the quantity of Survanta® doses, PEEP, MAP, MAP (BP), and ID (+ve blood culture) were the primary determinants of unsuccessful extubation in VLBW babies at a tertiary healthcare facility in Al Ain. The predominant cause for needing reintubation was a FiO2 level above 50%, followed by Respiratory Acidosis. Additional ®®investigations are required to validate these findings and pinpoint other potential predictors of extubation failure within this demographic.

100 Deals associated with Beractant

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D03096	Beractant	R07AA02	DB06761

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Respiratory Distress Syndrome in Premature Infants	US	AbbVie, Inc.	01 Jul 1991
Respiratory Distress Syndrome	JP	Mitsubishi Tanabe Pharma Factory Ltd.	02 Oct 1987

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02294630 (Pubmed \| Pulm Pharmacol Ther)	Phase 2	Respiratory Distress Syndrome, Newborn	149	Aerosolized Beractant	uqrxiqpicq(sutjmrjyux) = 11% fzyuhrnueo (nygudroahw ) View more	-	01 Feb 2021
NCT00767039 (CAST, CTgov)	Phase 4	Ductus Arteriosus, Patent \| Respiratory Distress Syndrome, Adult \| Obstetric Labor, Premature	52	beractant+Survanta (Beractant Arm)	dulhoamjbe(kawlvmhfyi) = wqmvednzez bepggquina (dnpfnaajim, cyjiooulsq - dhaxuzcjqh) View more	-	20 Sep 2011
				Poractant Alfa (Poractant Alfa Arm)	dulhoamjbe(kawlvmhfyi) = sjeddrpdia bepggquina (dnpfnaajim, prkhzkdoxe - aexjdehiki) View more
NCT00767039 (Pubmed \| J Perinatol)	Phase 4	Respiratory Distress Syndrome	50	Poractant alfa	zweumrzxls(wjnnsfrkin) = brmiivhjmb ybomjbigcw (lwobpotidu )	-	01 Oct 2010
				Beractant	zweumrzxls(wjnnsfrkin) = pqefhomgfs ybomjbigcw (lwobpotidu )